Table 2

Medication taken by study participants before entering the baseline phase of the study

Medication*Treatment group; no. of patients†
Levomepromazine (LMP) (n = 19)Chlorpromazine (CPZ) (n = 19)
Neuroleptic dose ≥ 1000 mg CPZ equivalents/d1918‡
Duration on 1000 mg CPZ equivalents/d
 ≥ 12 wk1816
 < 12 wk13
Mean dose in CPZ equivalents/d at baseline, (SD) [and range], mg1611 (879) [1000–3900]1872 (1333) [800–6250]‡
Duration medication was unchanged
 ≥ 12 wk53
 4 – < 12 wk1013
 < 4 wk43
Psychotropic medications limited to neuroleptics, anticholinergics and prn chloral hydrate
 ≥ 12 wk105
 4 – < 12 wk713
 < 4 wk21

  • SD = standard deviation; prn = as needed.

  • ↵* Between-group comparisons are not significantly different for any of the variables listed.

  • ↵† Unless otherwise indicated.

  • ↵‡ In 1 subject, the dose was reduced to 800 mg CPZ equivalents/d because of side effects before entry into baseline.